Skip to main content
SpringerLink
Log in

Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases

  • Published:
Current Medical Science Aims and scope Submit manuscript

Summary

This study compared the therapeutic effect of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) with that of EGFR-TKI plus whole brain radiotherapy (WBRT) on patients with EGFR mutation-positive lung adenocarcinoma and brain metastases. A total of 139 patients with lung adenocarcinoma and brain metastases treated with first-line EGFRTKI therapy from September 2008 to December 2017 were enrolled in this study. The study endpoints were intracranial time to progression (TTP) and overall survival (OS). The effects of clinical pathological parameters and EGFR gene status on the study endpoints were compared. The results showed that the intracranial TTP was significantly longer in EGFR-TKI plus WBRT group than in EGFR-TKI group (median 30.0 vs.18.2 months, χ2=10.824, P=0.001), but no significant difference in the OS was noted between the two groups (median 48.0 vs. 41.1 months, χ2=0.012, P=0.912). Also, there was no statistically significant difference in the OS between patients treated with early and late radiotherapy (P=0.849) and between those with asymptomatic and those with symptomatic intracranial metastases (P=0.189). The OS and intracranial TTP of patients with intracranial oligometastases (≤3 metastatic sites) were not significantly different from those of patients with multiple intracranial metastases (P=0.104 and P=0.357, respectively), and exon 19 and exon 21 mutations didn’t show significant effects on the OS and intracranial TTP of patients (P=0.418 and P=0.386, respectively). In conclusion, there was no statistically significant difference in the OS between the EGFR-TKI alone group and EGFR-TKI plus WBRT group. However, simultaneous use of WBRT was found to significantly prolong intracranial TTP and improve cerebral symptoms, and thus EGFR-TKI and WBRT combined may be clinically beneficial for patients with EGFR mutation-positive lung adenocarcinoma and brain metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Govindan R. Overcoming resistance to targeted therapy for lung cancer. New Engl J Med, 2015,372(18):1760–1761

    Article  PubMed  Google Scholar 

  2. Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol, 2013,31(15): 1803–1805

    Article  PubMed  Google Scholar 

  3. Bhatt VR, Kedia S, Kessinger A, et al. Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations. J Clin Oncol, 2013,31(25):3162–3164

    Article  Google Scholar 

  4. Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res, 2010,16(23):5873–5882

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Yi HG, Kim HJ, Kim YJ, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung cancer, 2009,65(1):80–84

    Article  PubMed  Google Scholar 

  6. Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol. 2013,24(4):993–999

    Article  PubMed  Google Scholar 

  7. Renaud S, Schaeffer M, Voegeli AC, et al. Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of nonsmall-cell lung cancer. Future Oncol, 2016,12(1):59–70

    Article  CAS  PubMed  Google Scholar 

  8. Li X, Wang Y, Wang J, et al. Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer. Int J Cancer, 2018,143(1):212–224

    Article  CAS  PubMed  Google Scholar 

  9. Cai L, Zhu JF, Zhang XW, et al. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. J Neurooncol, 2014,120(2):423–430

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Herman MA, Tremont-Lukats I, Meyers CA, et al. Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol, 2003,26(3):273–279

    PubMed  Google Scholar 

  11. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol, 2008,26(34):5589–5595

    Article  CAS  PubMed  Google Scholar 

  12. Matsumoto S, Takahashi K, Iwakawa R, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer, 2006,119(6):1491–1494

    Article  CAS  PubMed  Google Scholar 

  13. Baek MY, Ahn HK, Park KR, et al. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer. Korean J Intern Med, 2018,33(1):168–175

    Article  CAS  PubMed  Google Scholar 

  14. Shin SM, Cooper BT, Chachoua A, et al. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery. J Neurooncol, 2016,126(3):483–491

    Article  CAS  PubMed  Google Scholar 

  15. Wang WL, Li HW, Cao JZ, et al. Impacts of EGFR 19 exon mutations on brain metastases in treatment-naive patients with lung adenocarcinoma. Zhonghua Zhong Liu Za Zhi (Chinese), 2017,39(10):744–748

    CAS  Google Scholar 

  16. Gerber NK, Yamada Y, Rimner A, et al. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys, 2014,89(2):322–329

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res, 2005,65(8):3328–3335

    Article  CAS  Google Scholar 

  18. Lu Y, Fan Y. Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFRmutated non-small-cell lung cancer patients with brain metastasis. Onco Targets Ther, 2016,9:1135–1143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chen Y, Yang J, Li X, et al. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma. Cancer Sci, 2016,107(12):1800–1805

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zeng YD, Zhang L, Liao H, et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac J Cancer Prev, 2012,13(3):909–914

    Article  PubMed  Google Scholar 

  21. Byeon S, Ham JS, Sun JM, et al. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. Med Oncol, 2016,33(8):97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Jiang T, Su C, Li X, et al. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases. J Thorac Oncol, 2016,11(10):1718–1728

    Article  Google Scholar 

  23. Sung S, Lee SW, Kwak YK, et al. Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer. J Neurooncol, 2018,139(1):205–213

    Article  CAS  PubMed  Google Scholar 

  24. Johung KL, Yeh N, Desai NB, et al. Extended Survival and Prognostic Factors for Patients With ALKRearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J Clin Oncol, 2016,34(2):123–129

    Article  CAS  PubMed  Google Scholar 

  25. Martinez P, Mak RH, Oxnard GR. Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFRMutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases. JAMA Oncol, 2017,3(9):1274–1275

    Article  PubMed  Google Scholar 

  26. Wang H, Yu X, Fan Y, et al. Multiple treatment modalities for brain metastasis in patients with EGFRmutant non-small-cell lung cancer. Onco Targets Ther, 2018,11:2149–2155

    Article  PubMed  PubMed Central  Google Scholar 

  27. Gerdan L, Segedin B, Nagy V, et al. Brain metastasis from non-small cell lung cancer (NSCLC): prognostic importance of the number of involved extracranial organs. Strahlenther Onkol, 2014,190(1):64–67

    Article  CAS  PubMed  Google Scholar 

  28. Yu JY, Yu SF, Wang SH, et al. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21. Chin J Cancer, 2016,35:30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Zhou J, Ben S. Comparison of therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and L858R mutations in advanced lung adenocarcinoma and effect on cellular immune function. Thorac Cancer, 2018,9(2):228–233

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China

    Shao-bo Ke, Hu Qiu, Jia-mei Chen, Wei Shi & Yong-shun Chen

Authors
  1. Shao-bo Ke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hu Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jia-mei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong-shun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong-shun Chen.

Additional information

This study was supported by the Independent Research Project of Wuhan University (No. 2042016kf0127), the Natural Science Foundation of Hubei Province (No. 2017CFB245), the Guidance Fund of Renmin Hospital of Wuhan University (No. RMYD2018M48), and the National Natural Science Foundation of China (No. U1604175).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ke, Sb., Qiu, H., Chen, Jm. et al. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases. CURR MED SCI 38, 1062–1068 (2018). https://doi.org/10.1007/s11596-018-1984-0

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-018-1984-0

Key words

Search

Navigation